New research suggests that individuals who come off popular weight-loss injections like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who halt traditional lifestyle programs.
Research printed in a leading health publication demonstrates that while obese people often shed a large proportion of their total mass while on the medication, the mass returns at an average rate of 0.8 kg per month after stopping.
"Users buying these medications need to be informed of the danger of quick weight regain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
That rate of regain means a reversion to original mass in about one and a half years.
Comparing Treatments
The analysis, which examined dozens of trials involving over 9,000 of participants, compared the results of the injectable medications with older methods.
Researchers point out that people who shed pounds through lifestyle changes alone typically see a slower weight regain—approximately 0.1 kg a month—after stopping.
The Reason for the Fast Rebound
Experts believe the way of the jabs is key to understanding the accelerated rebound.
The injections imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication results in appetite is unsuppressed, making binge eating far more likely."
A Lifelong Condition?
Health authorities suggest the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Professionals contend that, considering the likelihood of weight regain, the therapy is often long-term.
This view is echoed by drug manufacturers, who note that the results "emphasize the persistent nature of excess weight," similar to managing conditions like diabetes.
Patient Accounts
Users who have come off the medication report a sudden resurgence of hunger.
"I experienced a switch flipping and you become extremely hungry," said one woman.
This difficulty is compounded if individuals have not developed lasting dietary or behavioural modifications during therapy.
Widespread Use
Survey data suggest that a significant number of people in the UK have tried these injections in the last 12 months, with demand continuing to grow.
- Use is more common among women than men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the medications through private prescriptions rather than public health services.
Ultimately, experts emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a magic cure and lasting health benefits likely depends on combined lifestyle support.
